agilon health, inc. (NYSE:AGL) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 PM ET

Company Participants

Leland Thomas - Senior Manager-Investor Relations
Steven Sell - Chief Executive Officer
Jeffrey Schwaneke - Chief Financial Officer

Conference Call Participants

Lisa Gill - JPMorgan
Justin Lake - Wolfe Research
Adam Ron - Bank of America
George Hill - Deutsche Bank
Sameer Patel - Evercore
Ryan Langston - TD Cowen
Stephen Baxter - Wells Fargo
Andrew Mok - Barclays
Jack Slevin - Jefferies
Michael Ha - Baird
Thomas Keller - RBC
Daniel Grosslight - Citi

Operator

Good afternoon and thank you for joining the agilon health Third Quarter 2024 Earnings Conference Call. My name is Kate and I will be the moderator for today's call. At this time all lines are in a listen-only mode and will be until the question and answer portion of the call. [Operator Instructions]

I would now like to turn the call over to Leland Thomas with agilon health. Leland, you may proceed.

Leland Thomas

Thank you operator. Good afternoon and welcome to the call. With me is our CEO, Steven Sell and our CFO Jeff Schwaneke. Following our prepared remarks, we will conduct a Q&A session.

Before we begin, I'd like to remind you that our remarks and responses to questions may include forward-looking statements. Actual results may differ materially from those stated or implied by forward-looking statements due to risks and uncertainties associated with our business. These risks and uncertainties are discussed in our SEC filings. Please note that we assume no obligations to update any forward-looking statements. Additionally, certain financial measures we will discuss in this call are non-GAAP financial measures. We believe that providing these measures helps investors gain a better and more complete understanding of our financial results, and is consistent with how management views our financial results. A reconciliation for these non-GAAP financial measures to the most comparable GAAP measures are available in the earnings press release and Form 8-K filed with the SEC.

And with that, let me turn things over to Steve.

.

Steven Sell

Thanks, Leland. Good afternoon and thank you for joining us. On today's call, I would like to walk you through the following: one, an overview of our third quarter financial results and updated 2024 guidance; two, the key actions we are taking to drive improved profitability, improve execution and further strengthen our business; three, despite the challenges of the last year, the underlying strength of our core business fundamentals and demand from payers and physicians; and four, the factors impacting our jumping off point for 2025 including an improved business mix exiting 2024.